2010

/Tag:2010

Oramed Pharmaceuticals Announces Publication in the Journal of Diabetes Science and Technology

Results Describe Preclinical Trials Demonstrating Retained GLP-1 Analog Activity When Delivered With Oramed's Oral Drug Delivery Formulations JERUSALEM, December 1, 2010 /PRNewswire via COMTEX/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( https://www.oramed.com), a developer of oral drug delivery solutions, announces a publication in the Journal [...]

2018-05-30T17:04:50+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD

JERUSALEM, November 15, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed [...]

2018-05-30T17:04:50+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present Results of an Oral Insulin Administration Study at the Tenth Annual Meeting of the Diabetes Technology Society (November 11-13, 2010; Bethesda, MD)

JERUSALEM, October 26, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (https://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented [...]

2018-05-30T17:04:50+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed’s Oral Insulin Capsules

JERUSALEM, Israel, July 7, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (https://www.oramed.com), a developer of oral delivery systems, today announced that Oramed entered into a Manufacturing Supply Agreement (MSA) with sanofi-aventis. According to the MSA, sanofi-aventis will supply Oramed with specified quantities of [...]

2018-05-30T17:04:51+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010

JERUSALEM, June 15, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) (https://www.oramed.com), a developer of alternative drug delivery systems, announced today that results of two of its clinical trials will be presented by Chief Scientific Officer Dr. Miriam Kidron, at the forthcoming 70th Annual [...]

2018-05-30T17:04:51+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the 9th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2010

Oramed to Present on Wednesday, June 16th at 11:50 a.m. (IDT) JERUSALEM, June 8, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), (https://www.oramed.com), a developer of oral delivery systems, today announced today that it was chosen to present at the 9th National Life Science [...]

2018-05-30T17:04:51+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism

JERUSALEM, May 26, 2010 /PRNewswire via COMTEX/ --Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (https://www.oramed.com), a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of [...]

2018-05-30T17:04:52+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors

JERUSALEM, May 18, 2010 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced that Dr. Michael Berelowitz, MD, joins Oramed Pharmaceuticals' Board of Directors. Dr. Berelowitz is currently Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit [...]

2018-05-30T17:04:52+00:00 Categories: Press Releases|Tags: |